Fri, May 2, 8:33 PM (20 days ago)
**89bio, Inc. (ETNB) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 (no commercial products) - **Net Loss:** $71.3 million (Q1 2025) vs. $51.6 million (Q1 2024) - **Cash & Equivalents:** $315.4 million (Q1 2025) vs. $126.1 million (Q1 2024) - **Operating Expenses:** $75.9 million (Q1 2025) vs. $57.3 million (Q1 2024) - **R&D Expenses:** $64.4 million (Q1 2025) vs. $47.4 million (Q1 2024) - **General & Admin. Expenses:** $11.5 million (Q1 2025) vs. $9.8 million (Q1 2024) - **Interest Expense:** $1.3 million (Q1 2025) vs. $0.9 million (Q1 2024) - **Interest Income:** $6.0 million (Q1 2025) vs. $6.6 million (Q1 2024) - **Profit Margins:** Negative due to high R&D and operational costs - **Cash Flow:** Positive $189.3 million (Q1 2025) due to public offering **Earnings Changes & Trends:** - **Increased R&D:** $17.0 million due to Phase 3 clinical programs - **Higher G&A:** $1.7 million due to increased headcount - **Positive Cash Flow:** $189.3 million from public offering **Quarterly Performance Discussion:** - **Operational Focus:** Pegozafermin development for MASH and SHTG - **Clinical Trials:** ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis for MASH, ENTRUST for SHTG - **Manufacturing:** Collaboration with BiBo for commercial supply **Future Operations Impact:** - **Funding:** $638.8 million in cash, cash equivalents, and marketable securities - **Uncertainties:** Clinical trial outcomes, regulatory approvals, competition - **Strategic Goals:** Continue R&D, seek additional funding, prepare for commercialization **Ticker:** ETNB **Full Name:** 89bio, Inc.